paulthepunk
10 Apr 2018
Re: Chairman Interview 100418 Pretty close to what has been said since VAL's inception! GLA,PTP.
Small Holding
10 Apr 2018
Re: Chairman Interview 100418 Q: Is there any outside interest?A: The progress we are making is bringing us closer and closer to commercialising these projects either by partnerships or licensing dealsQ: Cashwise you've got a bit of cash in the bank?A: We've got a bit of cash to keep us going for the forseeablePretty close to what was s
mol42
10 Apr 2018
Chairman Interview 100418 this afternoon[link]
clockwurktangerine
10 Apr 2018
Val work v UCL work Val bods take CEO salaries, no decent investor wants to truly back their research.In contrast UVL are on ackerdemic salaries and are too in their field. And all their work is documented and availalable. And ate gov backed.Val just money makers.
fredd1eboy
10 Apr 2018
Re: Deal? Well worth a read....[link]
Tired and Confused
10 Apr 2018
Deal? If it's so exciting, why has the capital raising been so difficult in the recent past? Why have we seen derisory terms, massive dilution and lenders of last resort with obscene 'gifting' of warrants? Who has had their snouts in the trough, directly or through backhanders if it has been such good proposition? VAL management can't have it both ways, have existing investors have been screwed by the like of Beaufort and management have complacently sat and watch them be diluted out of existence, not bothered as long as they get the funds to carry on research and pay wages. Lest we forget, management should be putting investors at the heart of everything they do and there has been little evidence that VAL have ever done that! I assume they will run out of money again soon, they always do. To be fair that's in the nature of this type of business which has no revenue but, I am getting a little tired of the rather hackneyed management ramping. The statement is also typically insensitive. NOW it is a realistic investable opportunity for potential shareholders. Well, what about the schmucks who have been funding VAL for years, was it not an investable proposition then? Have existing investors just been a bunch of naive 'cash cows'Whoever does VAL:'s PR ought to be shot!AIMHO and DYOR
fredd1eboy
10 Apr 2018
Re: RNS Results Personally I wouldnt mention a deal until rhe sp recovers to a realistic figure representing the realistic value of the research to date!
Small Holding
10 Apr 2018
Re: RNS Results The last sentence" The current momentum and exciting trajectory of both compounds offer potential investors an investable proposition and an attractive offering to joint venture partners." Well these joint venture partners don't seem to be falling over themselves to sign a de
Small Holding
10 Apr 2018
RNS Results VALIRX PLC("ValiRx", "the Company" or "the Group"
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 London, UK, 10 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, today announces its final results for the year ended 31 December 2017. HIGHLIGHTSOperational Highlights· Period of substantive and encouraging development across drug portfolio taking lead compounds to significant value inflection points;· Phase l/ll Clinical Trial of VAL201 has continued to demonstrate high safety and tolerability and has received MHRA approval to extend and expand the scope of the clinical trial to treat prostate cancer;· Completion of VAL401's Phase II Clinical Trial in patients with lung cancer - with trial data offering palliative stage patients an improvement in symptoms alongside improved survival prospects;· Period saw the optimized, commercially viable, 2nd generation development of the VAL101 molecule derived from ValiRx's proprietary GeneICE platform to shut down rebellious genes causing cancer and potentially some neurological disorders - preparation is underway for the compound's entry into the clinic;· VAL301 is in late pre-clinical phase initially for the treatment of the gynaecological condition, endometriosis - a reformulation of VAL201, which pre-clinical studies suggest does not compromise bone density or fertility. Final laboratory tests are underway prior to advancing the VAL301 compound into additional toxicology and then clinical trials;· Patent protection and portfolio coverage was extended for Val201 and VAL401 during the period with US patent granted for VAL201 in Q1 2018.Financial Highlights· Four Placings during the period raising £3.07m to advance the clinical trial of VAL201 and for the pre-clinical progress of other programmes;· Marked 36.4 % reduction in total comprehensive loss for the year to £3.02m (2016: Loss £4.75m) reflecting decrease in clinical trial expenditure on medicinal products;· Loss per share from continuing operations of 1.90p (2016: Loss 8.54p);· Cash and cash equivalents as at 31 December 2017 of £701,410 (2016: £560,763). Oliver de Giorgio-Miller, Non-Exec Chairman of ValiRx, commented:"I believe the Group has seen substantive and encouraging developments across its portfolio during the period to December 2017. The progress of our core clinical products, VAL201 and VAL401 has been substantial and both have reached significant value inflection points. The current momentum and exciting trajectory of both compounds offer potential investors an investable proposition and an attractive offering to joint venture partners."
Ripley94
03 Apr 2018
Re: buy recommendation from british bull... 03/03/18Topped again @ 2.485
Small Holding
03 Apr 2018
Re: Stubborn range trading Before the next dilutive fund raising we will not doubt get the obligatory positive RNS stating that the increased dose trial of VAL201 is going extremely well and there don't seem to be any noticable side effects.This positive RNS will be swiftly followed by an equity raising as the wages account, sorry the working capital fund, needs topping up.On December 18th when they announced the increased dose trial of VAL201, the RNS stated"This regulatory approval permits ValiRx to;· To substantially raise the dosing level in patients in order to reach therapeutic levels and reduce disease progression; · To assess at what stage in disease development the compound can be most effectively deployed in subsequent, larger, outcome-oriented clinical trials; and· To determine which route and with whom to take the project to its next stage - by the Company or with a partner."Well three and a half months later they still can't decide which of the large pharma's they want to do a deal with
Tired and Confused
03 Apr 2018
Re: Stubborn range trading Another week has gone by and the shares are dropping in the absence of news and anticipation of more dilutive fund raising. A buy at 2.5p is on the cards for those who want to average down. Maybe it has taken so long to get down to this territory that it might be better to wait until the next lot of fund raising before sinking any more money in?Who knows!AIMHO and DYOR
Tired and Confused
26 Mar 2018
Re: Reply from Dr Sarah Wollaston MP Read my earlier postI can't say much but I believe thing may be become very interesting in the near future!(general comment, not VAL specific, but if the cap fits......????)
Tired and Confused
26 Mar 2018
Stubborn range trading It just won't drop to 2.5p that's my average down point!I'm not sure whether that is a good or bad thing. Next lot of fund raising can't be far away now so probably will wait to the dilutional drop in price before getting the 2.5 price.Always a gamble because news could break but I don't think we are there yet.The only thing going for us PI's is maybe the new brokers will be less willing to employ 'pump and dump' tactic and who knows, maybe PI's might be offered a chance to take on new placing shares given we are the ones screwed each time they dilute us to death!AIMHO and DYOR
Maverick
20 Mar 2018
Patent granted in the US for Val201 Described as a cornerstone for the Company in the release.Exciting times ahead. Well done those holding.Maverick
